
|Articles|October 13, 2019
AAO 2019 Retina Street Team: J. Fernando Arevalo, MD, FACS
Author(s)AAO 2019 Retina Street Team
Advertisement
J. Fernando Arevalo, MD, FACS, shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment, at the 2019 annual meeting of the American Academy of Ophthalmology in San Francisco.
Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD), and whether the novel therapy is better than current treatment.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dry Eye Awareness Month: building a strong optometry-ophthalmology co-management model
2
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages
3
FDA grants priority review to Satralizumab sBLA for thyroid eye disease
4
REGENXBIO doses first patient in NAAVIGATE, phase 2b/3 sura-vec trial for diabetic retinopathy
5























